Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thymocyte selection-associated protein (THEMIS) is a highly conserved, T cell–specific signaling adaptor predominantly expressed during thymocyte development, particularly between the pre–T cell receptor (TCR) and the positive selection stages[1][2][4]. THEMIS plays an essential role in both positive and negative selection of thymocytes by integrating and sustaining TCR signals critical for CD4/CD8 lineage commitment and maturation[1][2][4][5]. Mechanistically, THEMIS modulates TCR signaling through its interaction with the adaptor protein GRB2 and the recruitment/inhibition of the tyrosine phosphatases SHP1 and SHP2, thereby fine-tuning kinase–phosphatase balance to set TCR signal thresholds required for effective selection outcomes[4][6][7]. THEMIS deficiency in mice results in impaired thymocyte selection, reduced numbers of single-positive T cells, and increased regulatory/memory T cell phenotypes, highlighting its pivotal role in T cell fate determination and immune system function[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thymocyte selection-associated protein (THEMIS).